Conbercept

Drug Profile

Conbercept

Alternative Names: KH902; Recombinant human VEGF receptor-Fc fusion protein

Latest Information Update: 28 Jul 2016

Price : $50

At a glance

  • Originator Chengdu Kanghong Biological Science & Technology
  • Class Eye disorder therapies; Recombinant fusion proteins
  • Mechanism of Action Angiogenesis inhibitors; Vascular endothelial growth factor A inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Wet age-related macular degeneration
  • Phase III Choroidal neovascularisation; Diabetic macular oedema
  • Phase II Retinal oedema

Most Recent Events

  • 02 Sep 2015 The phase III SHINY trial for Choroidal neovascularisation is ongoing in China (NCT01809223)
  • 01 Jul 2014 Chengdu Kanghong plans the phase III Sailing trial for Diabetic macular oedema in China (NCT02194634)
  • 27 Mar 2014 Chengdu Kanghong Biotech completes enrolment in the phase II LAMP trial for Wet age-related macular degeneration (resulting in very low vision) in China (NCT02098720)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top